Drug Profile
SNS 314
Alternative Names: SNS-314Latest Information Update: 02 Mar 2021
Price :
$50
*
At a glance
- Originator Sunesis Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Solid tumours
Most Recent Events
- 24 Feb 2021 Sunesis Pharmaceuticals has been merged with Viracta Therapeutics to form Viracta Therapeutics
- 26 Jan 2011 CyDex Pharmaceuticals has been acquired by Ligand Pharmaceuticals
- 05 Mar 2009 Sunesis completes a phase I trial in Solid tumours in USA